Graybug Vision (NASDAQ:GRAY) Trading Down 4.1%

Graybug Vision, Inc. (NASDAQ:GRAYGet Free Report)’s stock price dropped 4.1% on Thursday . The stock traded as low as $4.40 and last traded at $4.48. Approximately 10,987 shares were traded during mid-day trading, an increase of 407% from the average daily volume of 2,165 shares. The stock had previously closed at $4.67.

Graybug Vision Stock Up 0.7 %

The firm has a 50 day moving average of $4.73 and a two-hundred day moving average of $4.80. The firm has a market capitalization of $7.09 million, a price-to-earnings ratio of -0.18 and a beta of 1.20.

About Graybug Vision

(Get Free Report)

Graybug Vision, Inc, a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema.

Featured Articles

Receive News & Ratings for Graybug Vision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Graybug Vision and related companies with MarketBeat.com's FREE daily email newsletter.